(BG) Bunge - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: CH1300646267
Stock:
Total Rating 61
Risk 67
Buy Signal 0.34
| Risk 5d forecast | |
|---|---|
| Volatility | 26.9% |
| Relative Tail Risk | -7.30% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.68 |
| Alpha | 62.48 |
| Character TTM | |
|---|---|
| Beta | 0.253 |
| Beta Downside | 0.653 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.82% |
| CAGR/Max DD | 0.26 |
EPS (Earnings per Share)
Revenue
Description: BG Bunge
Bunge Global SA operates as an agribusiness and food company worldwide. It operates through four segments: Soybean Processing and Refining, Softseed Processing and Refining, Other Oilseeds Processing and Refining, and Grain Merchandising and Milling. The Soybean Processing and Refining segment is involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of soybeans and soybean related products, as well as biodiesel and fertilizer production and distribution for the food, animal feed and biofuel industries. The Softseed Processing and Refining segment is involved in the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of softseeds and softseed related products, as well as biodiesel production and distribution. The Other Oilseeds Processing and Refining Segment is involved in products of a specialty nature, including the purchase, storage, transportation, processing, distribution, refining, marketing, and sale of these related products. The Grain Merchandising and Milling segment is involved in the purchase, storage, transportation, distribution, and marketing of commodities primarily consisting of corn, wheat, barley, cotton, pulses, and sugar; milling of wheat and sugar; and related services including ocean freight and financial services. Bunge Global SA was founded in 1818 and is headquartered in Chesterfield, Missouri.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: 816.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.44 > 1.0 |
| NWC/Revenue: 13.17% < 20% (prev 16.05%; Δ -2.88% < -1%) |
| CFO/TA 0.02 > 3% & CFO 834.0m > Net Income 816.0m |
| Net Debt (15.82b) to EBITDA (2.46b): 6.42 < 3 |
| Current Ratio: 1.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.0m) vs 12m ago 39.66% < -2% |
| Gross Margin: 4.85% > 18% (prev 0.06%; Δ 478.3% > 0.5%) |
| Asset Turnover: 202.6% > 50% (prev 213.3%; Δ -10.70% > 0%) |
| Interest Coverage Ratio: 2.81 > 6 (EBITDA TTM 2.46b / Interest Expense TTM 628.0m) |
Altman Z'' 3.18
| A: 0.21 (Total Current Assets 24.39b - Total Current Liabilities 15.13b) / Total Assets 44.53b |
| B: 0.30 (Retained Earnings 13.15b / Total Assets 44.53b) |
| C: 0.05 (EBIT TTM 1.76b / Avg Total Assets 34.71b) |
| D: 0.49 (Book Value of Equity 13.15b / Total Liabilities 27.11b) |
| Altman-Z'' Score: 3.18 = A |
Beneish M -2.29
| DSRI: 1.07 (Receivables 3.87b/2.74b, Revenue 70.33b/53.11b) |
| GMI: 1.32 (GM 4.85% / 6.39%) |
| AQI: 1.27 (AQ_t 0.14 / AQ_t-1 0.11) |
| SGI: 1.32 (Revenue 70.33b / 53.11b) |
| TATA: -0.00 (NI 816.0m - CFO 834.0m) / TA 44.53b) |
| Beneish M-Score: -2.29 (Cap -4..+1) = BBB |
What is the price of BG shares?
As of March 01, 2026, the stock is trading at USD 120.65 with a total of 1,725,856 shares traded.
Over the past week, the price has changed by -1.07%, over one month by +4.47%, over three months by +26.31% and over the past year by +69.79%.
Over the past week, the price has changed by -1.07%, over one month by +4.47%, over three months by +26.31% and over the past year by +69.79%.
Is BG a buy, sell or hold?
Bunge has received a consensus analysts rating of 3.90.
Therefore, it is recommended to buy BG.
- StrongBuy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 126 | 4.4% |
| Analysts Target Price | 126 | 4.4% |
BG Fundamental Data Overview February 27, 2026
P/E Trailing = 28.6274
P/E Forward = 9.5877
P/S = 0.3337
P/B = 1.5262
P/EG = 1.7053
Revenue TTM = 70.33b USD
EBIT TTM = 1.76b USD
EBITDA TTM = 2.46b USD
Long Term Debt = 8.83b USD (from longTermDebt, last quarter)
Short Term Debt = 5.93b USD (from shortTermDebt, last quarter)
Debt = 16.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.82b USD (from netDebt column, last quarter)
Enterprise Value = 39.29b USD (23.47b + Debt 16.95b - CCE 1.14b)
Interest Coverage Ratio = 2.81 (Ebit TTM 1.76b / Interest Expense TTM 628.0m)
EV/FCF = 132.7x (Enterprise Value 39.29b / FCF TTM 296.0m)
FCF Yield = 0.75% (FCF TTM 296.0m / Enterprise Value 39.29b)
FCF Margin = 0.42% (FCF TTM 296.0m / Revenue TTM 70.33b)
Net Margin = 1.16% (Net Income TTM 816.0m / Revenue TTM 70.33b)
Gross Margin = 4.85% ((Revenue TTM 70.33b - Cost of Revenue TTM 66.92b) / Revenue TTM)
Gross Margin QoQ = 4.25% (prev 4.80%)
Tobins Q-Ratio = 0.88 (Enterprise Value 39.29b / Total Assets 44.53b)
Interest Expense / Debt = 1.27% (Interest Expense 216.0m / Debt 16.95b)
Taxrate = 25.40% (288.0m / 1.13b)
NOPAT = 1.31b (EBIT 1.76b * (1 - 25.40%))
Current Ratio = 1.61 (Total Current Assets 24.39b / Total Current Liabilities 15.13b)
Debt / Equity = 0.98 (Debt 16.95b / totalStockholderEquity, last quarter 17.37b)
Debt / EBITDA = 6.42 (Net Debt 15.82b / EBITDA 2.46b)
Debt / FCF = 53.44 (Net Debt 15.82b / FCF TTM 296.0m)
Total Stockholder Equity = 13.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.35% (Net Income 816.0m / Total Assets 44.53b)
RoE = 5.98% (Net Income TTM 816.0m / Total Stockholder Equity 13.65b)
RoCE = 7.84% (EBIT 1.76b / Capital Employed (Equity 13.65b + L.T.Debt 8.83b))
RoIC = 5.53% (NOPAT 1.31b / Invested Capital 23.78b)
WACC = 4.38% (E(23.47b)/V(40.42b) * Re(6.85%) + D(16.95b)/V(40.42b) * Rd(1.27%) * (1-Tc(0.25)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 15.18%
[DCF] Terminal Value 80.82% ; FCFF base≈387.2m ; Y1≈254.2m ; Y5≈116.0m
[DCF] Fair Price = N/A (negative equity: EV 3.70b - Net Debt 15.82b = -12.12b; debt exceeds intrinsic value)
EPS Correlation: -72.81 | EPS CAGR: -18.37% | SUE: 0.23 | # QB: 0
Revenue Correlation: 1.23 | Revenue CAGR: 11.35% | SUE: 2.66 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.82 | Chg7d=+0.000 | Chg30d=-1.013 | Revisions Net=-3 | Analysts=7
EPS current Year (2026-12-31): EPS=8.13 | Chg7d=+0.000 | Chg30d=-0.816 | Revisions Net=-5 | Growth EPS=+7.3% | Growth Revenue=+29.1%
EPS next Year (2027-12-31): EPS=9.94 | Chg7d=+0.000 | Chg30d=-0.288 | Revisions Net=+0 | Growth EPS=+22.3% | Growth Revenue=+3.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = +93.8% (Analyst 98.3% - Implied 4.5%)
P/E Forward = 9.5877
P/S = 0.3337
P/B = 1.5262
P/EG = 1.7053
Revenue TTM = 70.33b USD
EBIT TTM = 1.76b USD
EBITDA TTM = 2.46b USD
Long Term Debt = 8.83b USD (from longTermDebt, last quarter)
Short Term Debt = 5.93b USD (from shortTermDebt, last quarter)
Debt = 16.95b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.82b USD (from netDebt column, last quarter)
Enterprise Value = 39.29b USD (23.47b + Debt 16.95b - CCE 1.14b)
Interest Coverage Ratio = 2.81 (Ebit TTM 1.76b / Interest Expense TTM 628.0m)
EV/FCF = 132.7x (Enterprise Value 39.29b / FCF TTM 296.0m)
FCF Yield = 0.75% (FCF TTM 296.0m / Enterprise Value 39.29b)
FCF Margin = 0.42% (FCF TTM 296.0m / Revenue TTM 70.33b)
Net Margin = 1.16% (Net Income TTM 816.0m / Revenue TTM 70.33b)
Gross Margin = 4.85% ((Revenue TTM 70.33b - Cost of Revenue TTM 66.92b) / Revenue TTM)
Gross Margin QoQ = 4.25% (prev 4.80%)
Tobins Q-Ratio = 0.88 (Enterprise Value 39.29b / Total Assets 44.53b)
Interest Expense / Debt = 1.27% (Interest Expense 216.0m / Debt 16.95b)
Taxrate = 25.40% (288.0m / 1.13b)
NOPAT = 1.31b (EBIT 1.76b * (1 - 25.40%))
Current Ratio = 1.61 (Total Current Assets 24.39b / Total Current Liabilities 15.13b)
Debt / Equity = 0.98 (Debt 16.95b / totalStockholderEquity, last quarter 17.37b)
Debt / EBITDA = 6.42 (Net Debt 15.82b / EBITDA 2.46b)
Debt / FCF = 53.44 (Net Debt 15.82b / FCF TTM 296.0m)
Total Stockholder Equity = 13.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.35% (Net Income 816.0m / Total Assets 44.53b)
RoE = 5.98% (Net Income TTM 816.0m / Total Stockholder Equity 13.65b)
RoCE = 7.84% (EBIT 1.76b / Capital Employed (Equity 13.65b + L.T.Debt 8.83b))
RoIC = 5.53% (NOPAT 1.31b / Invested Capital 23.78b)
WACC = 4.38% (E(23.47b)/V(40.42b) * Re(6.85%) + D(16.95b)/V(40.42b) * Rd(1.27%) * (1-Tc(0.25)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 15.18%
[DCF] Terminal Value 80.82% ; FCFF base≈387.2m ; Y1≈254.2m ; Y5≈116.0m
[DCF] Fair Price = N/A (negative equity: EV 3.70b - Net Debt 15.82b = -12.12b; debt exceeds intrinsic value)
EPS Correlation: -72.81 | EPS CAGR: -18.37% | SUE: 0.23 | # QB: 0
Revenue Correlation: 1.23 | Revenue CAGR: 11.35% | SUE: 2.66 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.82 | Chg7d=+0.000 | Chg30d=-1.013 | Revisions Net=-3 | Analysts=7
EPS current Year (2026-12-31): EPS=8.13 | Chg7d=+0.000 | Chg30d=-0.816 | Revisions Net=-5 | Growth EPS=+7.3% | Growth Revenue=+29.1%
EPS next Year (2027-12-31): EPS=9.94 | Chg7d=+0.000 | Chg30d=-0.288 | Revisions Net=+0 | Growth EPS=+22.3% | Growth Revenue=+3.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = +93.8% (Analyst 98.3% - Implied 4.5%)